Adamis Pharmaceuticals
2658 Del Mar Heights Road
Suite 555
Del Mar
California
92014
United States
192 articles about Adamis Pharmaceuticals
-
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
9/7/2023
Adamis Pharmaceuticals Corporation announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders.
-
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/21/2023
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
8/4/2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.
-
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
8/2/2023
Adamis Pharmaceuticals Corporation today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit.
-
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
7/28/2023
Adamis Pharmaceuticals Corporation today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
-
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
6/26/2023
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226).
-
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
6/22/2023
Adamis Pharmaceuticals Corporation today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Director, Dr. Rahul Gupta.
-
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
5/25/2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.
-
Adamis Pharmaceuticals Announces Reverse Stock Split - May 19, 2023
5/19/2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.
-
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/15/2023
Adamis Pharmaceuticals Corporation announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
5/8/2023
Adamis Pharmaceuticals announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 pm PT to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 am PT as well as the proposals to be considered and acted upon at the meeting.
-
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
3/16/2023
Adamis Pharmaceuticals Corporation announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
3/14/2023
Adamis Pharmaceuticals Corporation announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update.
-
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
3/14/2023
Adamis Pharmaceuticals Corporation announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share and accompanying warrants, pursuant to a registered direct offering.
-
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
2/27/2023
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”).
-
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
2/22/2023
Adamis Pharmaceuticals Corporation announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on Nasdaq, pursuant to an extension through June 26, 2023 to evidence compliance with the $1.00 bid price requirement and its continued compliance with all other applicable criteria for continued listing on the Nasdaq Capital Market.
-
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
Adamis Pharmaceuticals Corporation reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
11/7/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it will host an investor conference call on Monday, November 14, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the third quarter 2022 as well as provide a corporate update.
-
Adamis Announces Review of Strategic Alternatives
10/3/2022
Adamis Pharmaceuticals Corporation announced that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value.
-
Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more reported updates in solid tumors, migraine, ALS and MDMA drug discovery.